Thiazolidinediones And Risk Of Breast Cancer: A Meta-analysis

Objective: We applied Meta-analysis method to explore that if thereis association of thiazolidinediones and breast cancer,so as to provide a reference basis for the association of thiazolidinediones and cancer.Methods:We take ―Thiazolidinediones 、 pioglitazone 、 rosiglitazone 、 Breast Neoplasms‖ as keywords to formulate search statagy about Thiazolidinediones and female breast cancer.We searched the following key electronic biomedical databases frominception through May1,2016: Pub Med、Embase、OVID,Co Chrane Library、Biosis、CBM、CNKI and other Chinese databases.Study design included randomized controlled trials(RCTs)、cohort studies and nested case-control studies.Objects of study are type 2 diabetes and thiazolidinediones are exposure factor.Studies were selected according to inclusion criteria and elimination criteria and scored every study according to pertinent rating scales.We extracted data from selected studies to summary relative risk of RCTs \cohort studies and odds ratio of nested case-control studies by Revman 5.3 and STATA12.0 software.Fixed-effects model or random-effects model were choose by heterogeneity and took sensitivity analyses and risk of publication bias.Results:The analysis of 15 studies concluded 4 RCTs、9 cohort studies and 2 nested case-control studies which involving a total of 2479419 objects.1.Estimates from the use ofany thiazolidinediones and breast cancer: RCTs(pooled RR=0.67,95%CI:0.39 ~1.12,I2=21.4%,n=4),observational studies(pooled RR=0.87,95%CI:0.77~0.98,I2=59.6%,n=13).Estimates of pioglitazone and breast cancer:(RR=0.92,95%CI:0.85~0.99,I2=0.0%,n=5).The risk of rosiglitazone and breast cancer:(RR=0.83,95%CI:0.45~1.51,I2=16.6%,n=2),the association was not statistically significant.Conclusion:1.Observational studies suggest that TZDs can decrease the risk of breast cancer while the result of RCTs prove the assoation is not siginificant.2.Our findings suggest that use of TZDs or pioglitazone is associated with decreased risk of breast cancer.3.The evidence cannot prove that there is assoation between rosiglitazone and breast cancer.